Tafamidis

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: January 06, 2026

Associations of Tafamidis With New Atrial Fibrillation Risk in Transthyretin Cardiomyopathy.

Journal: JACC. Clinical electrophysiology

Published: January 03, 2026

Misfolded Proteins in the Eye - Vitreous Amyloidosis.

Misfolded Proteins in the Eye - Vitreous Amyloidosis.

MR-ProADM Predicts Mortality and Heart Failure Events in ATTR Cardiac Amyloidosis.

MR-ProADM Predicts Mortality and Heart Failure Events in ATTR Cardiac Amyloidosis.

A Rare Presentation of Pulmonary Transthyretin Amyloidosis With Persistent Ground-Glass Opacity Diagnosed by Transbronchial Lung Biopsy.

A Rare Presentation of Pulmonary Transthyretin Amyloidosis With Persistent Ground-Glass Opacity Diagnosed by Transbronchial Lung Biopsy.

Pyrophosphate Scintigraphy Changes After Tafamidis Therapy - Proposed Novel Index From Quantitative Single-Photon Emission Computed Tomography.

Pyrophosphate Scintigraphy Changes After Tafamidis Therapy - Proposed Novel Index From Quantitative Single-Photon Emission Computed Tomography.

Acoramidis in transthyretin amyloid cardiomyopathy: expanding evidence from ATTRibute-CM.

Acoramidis in transthyretin amyloid cardiomyopathy: expanding evidence from ATTRibute-CM.

Exploring Tafamidis Effects Through PBPK-QSP Modelling.

Exploring Tafamidis Effects Through PBPK-QSP Modelling.

Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study.

Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study.

Transthyretin Cardiac Amyloidosis With Reduced Ejection Fraction in a 47-Year-Old Man: An Unusual Presentation.

Transthyretin Cardiac Amyloidosis With Reduced Ejection Fraction in a 47-Year-Old Man: An Unusual Presentation.

Response to 'Interpreting tafamidis effectiveness within the evolving phenotype of contemporary ATTRwt cardiomyopathy'.

Response to 'Interpreting tafamidis effectiveness within the evolving phenotype of contemporary ATTRwt cardiomyopathy'.

Impact of disease-modifying therapies on imaging parameters in cardiac amyloidosis: A systematic review and meta-analysis.

Impact of disease-modifying therapies on imaging parameters in cardiac amyloidosis: A systematic review and meta-analysis.

Long-term outcome of acquired transthyretin amyloidosis.

Long-term outcome of acquired transthyretin amyloidosis.

Associations of Tafamidis With New Atrial Fibrillation Risk in Transthyretin Cardiomyopathy.

Associations of Tafamidis With New Atrial Fibrillation Risk in Transthyretin Cardiomyopathy.

Pyrophosphate Scintigraphy Changes After Tafamidis Therapy　- Proposed Novel Index From Quantitative Single-Photon Emission Computed Tomography.

Pyrophosphate Scintigraphy Changes After Tafamidis Therapy　- Proposed Novel Index From Quantitative Single-Photon Emission Computed Tomography.